Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Deals Business Strategies ImmunoOncology

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

  • News

Executive Summary

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

You may also be interested in...



With Celgene Acquisition Closed, Bristol Faces Major Milestones

Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue. 

Harpoon Finds A Blood Cancer Partner In AbbVie

The immuno-oncology developer optioned its BCMA-targeting drug to AbbVie for $50m upfront, while it plans to retain a focus on solid-tumor candidates.

Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos

$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.

Table

View full table

Related Content

Scrip Scrip Scrip Generics Bulletin Generics Bulletin Scrip Scrip

Topics

Related Companies

Related Deals

Tags:
Deals Business Strategies ImmunoOncology
UsernamePublicRestriction

Register

SC141232

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By